Psychiatric treatment of persons with HIV/AIDS: An HIV-psychiatry consensus survey of current practices

Psychosomatics

Volumn 51, Issue 6, 2010, Pages 480-488

  Freudenreich, Oliver ^a   Goforth, Harold W ^b   Cozza, Kelly L ^e   Mimiaga, Matthew J ^a   Safren, Steven A ^e   Bachmann, Grace ^c   Cohen, Mary Ann ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Academy of Psychosomatic Medicine   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; CHLORPROMAZINE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESCITALOPRAM; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

AIDS PATIENT; ANXIETY DISORDER; ARTICLE; CLINICAL PRACTICE; CONSENSUS; DEPRESSION; DRUG CHOICE; HEALTH CARE ORGANIZATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MANIA; PSYCHOSIS;

EID: 78649655790     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1176/appi.psy.51.6.480     Document Type: Article

References (41)

1. Adewuya AO, Afolabi MO, Ola BA, et al: Psychiatric disorders among the HIV-positive population in Nigeria: a control study. J Psychosom Res 2007; 63:203-206 (Pubitemid 47088555)
2. Bing EG, Burnam MA, Longshore D, et al: Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721-728 (Pubitemid 32717795)
3. Petrushkin H, Boardman J, Ovuga E: Psychiatric disorders in HIV-positive individuals in urban Uganda. Psychiatr Bull 2005; 29:455-458 (Pubitemid 41819271)
4. Wormser G: AIDS and other manifestations of HIV infection, in AIDS Psychiatry: Psychiatric and Palliative Care, and Pain Management, 4th Edition. Edited by Cohen MA, Alfonso CA. San Diego, CA, Elsevier Academic Press, 2004
5. Horberg MA, Silverberg MJ, Hurley LB, et al: Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47:384-390
6. Leserman J: Role of depression, stress, and trauma in HIV disease progression. Psychosom Med 2008; 70:539-545
7. Olatunji BO, Mimiaga MJ, O'Cleirigh C, et al: Review of treatment studies of depression in HIV. Topics in HIV Med 2006; 14:112-124
8. Fernandez F, Ruiz P (eds): Psychiatric Aspects of HIV/AIDS. Philadelphia, PA, Lippincott Williams & Wilkins, 2006
9. Cohen MA, Gorman JM (eds): Comprehensive Textbook of AIDS Psychiatry. New York, NY, Oxford University Press, 2008
10. American Psychiatric Association: http://www.psychiatryonline. com/pracGuide/pracGuideTopic-4.aspx. (last accessed 05/08/09)
11. Breitbart W, Marotta R, Platt MM, et al: A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231-237 (Pubitemid 26038965)
12. Breitbart W, Rosenfeld B, Kaim M, et al: A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001; 161:411-420 (Pubitemid 32116559)
13. Elliott AJ, Uldall KK, Bergam K, et al: Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 1998; 155:367-372
14. Rabkin JG, Wagner GJ, Rabkin R: Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999; 156:101-107
15. Rabkin JG, Wagner GJ, McElhiney MC, et al: Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol 2004; 24:379-385
16. Rabkin JG, McElhiney MC, Rabkin R, et al: Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of non-major depression in patients with HIV/AIDS. Am J Psychiatry 2006; 163:59-66 (Pubitemid 43050104)
17. Wagner GJ, Rabkin R: Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61:436-440
18. Expert Consensus Guidelines: http://www.psychguides.com/ schizophrenia. (last accessed 05/08/09)
19. Wynn GH, Zapor MJ, Smith BH, et al: Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. Psychosomatics 2004; 45:262-270
20. Zapor MJ, Cozza KL, Wynn GH, et al: Antiretrovirals, part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 2004; 45:524-535
21. Sandson NB, Armstrong SC, Cozza KL: An overview of psychotropic drug-drug interactions. Psychosomatics 2005; 46:464-494
22. Omonuwa T, Goforth HW, Preud'homme X, et al: The pharmacologic management of insomnia in patients with HIV. J Clin Sleep Med 2009; 5:251-262
23. Wynn GH, Oesterheld JR, Cozza KL, et al: Clinical Manual of Drug Interaction Principles for Medical Practice: Oesterheld JR: 3A4. Washington, DC, American Psychiatric Press, 2009, pp 111-112
24. Juncos JL, Roberts VJ, Evatt ML, et al: Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004; 19:29-35 (Pubitemid 38559617)
25. Kumar AM, Borodowsky I, Fernandez B, et al: Human immunodeficiency virus type 1: RNA levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol 2007; 13:210-224 (Pubitemid 47050647)
26. Menza MA, Murray GM, Holmes VF, et al: Decreased extrapyramidal symptoms with intravenous haloperidol. J Clin Psychiatry 1987; 48:278-280
27. Ayuso JL: Use of psychotropic drugs in patients with HIV infection. Drugs 1994; 47:599-610
28. Romanelli F, Jennings HR, Nath A, et al: Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology 2000; 54:1404-1407 (Pubitemid 30210456)
29. Cozza KL, Swanton EJ, Humphreys CW: Hepatotoxicity with combination of valproic acid, ritonavir, and nevirapine: a case report. Psychosomatics 2000; 41:452-453
30. Stahl SM, Mignon L, Meyer JM: Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009; 119:171-179
31. Ballard C, Hanney ML, Theodoulou M, et al: The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised, placebo-controlled trial. Lancet Neurol 2009; 8:151-157
32. Safren SA, O'Cleirigh C, Tan JY, et al: A randomized, controlled trial of cognitive-behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol 2009; 28:1-10
33. Fremont WP, Nastasi R, Newman N, et al: Comfort level of pediatricians and family-medicine physicians diagnosing and treating child and adolescent psychiatric disorders. Int J Psychiatry Med 2008; 38:153-168
34. Scholz T, Krichevsky A, Sumarto A, et al: Peripheral nerve injuries: an international survey of current treatments and future perspectives. J Reconstr Microsurg 2009; 25:339-344
35. Reid S, Dwyer J: Insomnia in HIV infection: a systematic review of prevalence, correlates, and management. Psychosom Med 2006; 67:260-269
36. Douaihy AB, Stowell KR, Kohnen S, et al: Psychiatric aspects of comorbid HIV/AIDS and pain, part 1. AIDS Read 2007; 17:310-314
37. Paddison J, Fricchione G, Gandhi RT, et al: Fatigue in psychiatric HIV patients: a pilot study of psychological correlates. Psychosomatics 2009; 455-460
38. Sacktor N, Lyles RH, Skolasky R, et al: HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-260
39. Nejad SH, Gandhi R, Freudenreich O: Clozapine use in HIV-infected schizophrenia patients: a case-based discussion. Psychosomatics 2009; 626-632
40. Lera G, Zirulnik J: Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 1999; 14:128-131 (Pubitemid 29224687)
41. Fincham JE: Response rates and responsiveness for surveys, standards, and the journal. Am J Pharm Educ 2008; 72:1-3